BACKGROUND: Risk factors for heart failure (HF) have not been reported previously in a nationally representative sample of dialysis patients. METHODS: We conducted a historic cohort study of 1,995 patients enrolled in the US Renal Data System Dialysis Morbidity and Mortality Study Wave 2 who were Medicare eligible at the study start and were followed up until December 31, 1999, or receipt of a renal transplant. Cox regression analysis was used to model associations with time to first hospitalization for both recurrent and de novo HF (International Classification of Diseases, Ninth Revision code 428.x), defined as patients with and without a history of HF, respectively. RESULTS: The incidence density of HF was 71/1,000 person-years. Angiotensin-converting enzyme inhibitors and beta-blockers were each used in less than 25% of patients with a known history of HF. A history of coronary heart disease was associated with an increased total risk for HF, as were hemodialysis (versus peritoneal dialysis), aspirin use, and a history of diabetes. However, hemodialysis and aspirin use were the only factors associated with both de novo and recurrent HF. Widened pulse pressure was associated with de novo HF. The mortality rate after HF was 83% at 3 years (adjusted hazard ratio for mortality, 2.10; 95% confidence interval, 1.80 to 2.45; P < 0.0001). CONCLUSION: In chronic dialysis patients, hemodialysis and aspirin use were associated with increased risk for both total and de novo HF. Hospitalized HF was associated with a significantly increased risk for death.
BACKGROUND: Risk factors for heart failure (HF) have not been reported previously in a nationally representative sample of dialysis patients. METHODS: We conducted a historic cohort study of 1,995 patients enrolled in the US Renal Data System Dialysis Morbidity and Mortality Study Wave 2 who were Medicare eligible at the study start and were followed up until December 31, 1999, or receipt of a renal transplant. Cox regression analysis was used to model associations with time to first hospitalization for both recurrent and de novo HF (International Classification of Diseases, Ninth Revision code 428.x), defined as patients with and without a history of HF, respectively. RESULTS: The incidence density of HF was 71/1,000 person-years. Angiotensin-converting enzyme inhibitors and beta-blockers were each used in less than 25% of patients with a known history of HF. A history of coronary heart disease was associated with an increased total risk for HF, as were hemodialysis (versus peritoneal dialysis), aspirin use, and a history of diabetes. However, hemodialysis and aspirin use were the only factors associated with both de novo and recurrent HF. Widened pulse pressure was associated with de novo HF. The mortality rate after HF was 83% at 3 years (adjusted hazard ratio for mortality, 2.10; 95% confidence interval, 1.80 to 2.45; P < 0.0001). CONCLUSION: In chronic dialysis patients, hemodialysis and aspirin use were associated with increased risk for both total and de novo HF. Hospitalized HF was associated with a significantly increased risk for death.
Authors: Tara I Chang; David Shilane; Steven M Brunelli; Alfred K Cheung; Glenn M Chertow; Wolfgang C Winkelmayer Journal: Am Heart J Date: 2011-07-18 Impact factor: 4.749
Authors: Stephen M S Ting; Hasan Iqbal; Hemali Kanji; Thomas Hamborg; Nicolas Aldridge; Nithya Krishnan; Chris H E Imray; Prithwish Banerjee; Rosemary Bland; Robert Higgins; Daniel Zehnder Journal: J Am Soc Nephrol Date: 2013-11-14 Impact factor: 10.121
Authors: Nisha Bansal; Jason Roy; Hsiang-Yu Chen; Rajat Deo; Mirela Dobre; Michael J Fischer; Elyse Foster; Alan S Go; Jiang He; Martin G Keane; John W Kusek; Emile Mohler; Sankar D Navaneethan; Mahboob Rahman; Chi-Yuan Hsu Journal: Am J Kidney Dis Date: 2018-05-18 Impact factor: 8.860
Authors: Angela Yee Moon Wang; K Scott Brimble; Gillian Brunier; Stephen G Holt; Vivekanand Jha; David W Johnson; Shin-Wook Kang; Jeroen P Kooman; Mark Lambie; Chris McIntyre; Rajnish Mehrotra; Roberto Pecoits-Filho Journal: Perit Dial Int Date: 2015 Jul-Aug Impact factor: 1.756
Authors: Angelo M de Mattos; Andrew Siedlecki; Robert S Gaston; Gilbert J Perry; Bruce A Julian; Clifton E Kew; Mark H Deierhoi; Carlton Young; John J Curtis; Ami E Iskandrian Journal: J Am Soc Nephrol Date: 2008-03-27 Impact factor: 10.121